Role of Vasopressin Receptor 2 and 3 in ACTH-Secreting Tumors and their Potential Therapeutic Implications

Abstract

Purpose We investigated the expression of vasopressin receptor 2 and 3 on corticotrophin tumor cells, their role in regulating ACTH secretion, and their potential therapeutic implications.

Methods We retrospectively assessed 52 hospitalized patients with pathologically confirmed ACTH-secreting tumors. The expression of vasopressin receptor 2 and 3 was explored via qualitative and quantitative immunohistochemistry analyses. The role of vasopressin receptors in regulating ACTH secretion was further studied in the AtT-20 cell line.

Results Among 50 cases of pituitary corticotrophin adenoma, 31 were vasopressin receptor 2 positive, 38 were vasopressin receptor 3 positive, and 24 were both vasopressin receptor 2 and 3 positive. Two patients with ectopic ACTH syndrome were vasopressin receptor 3 positive, and one was also vasopressin receptor 2 positive. In 12 patients who underwent bilateral inferior petrosal sinus sampling before surgery, the central ACTH increment ratio after desmopressin stimulation was correlated with vasopressin receptor 2 but not with vasopressin receptor 3 staining intensity. In an in vitro study, the expression of both vasopressin receptor 2 and 3 on AtT-20 cells was confirmed. The vasopressin receptor 2 antagonist Tolvaptan inhibited desmopressin-induced ACTH secretion in a dose-dependent manner.

Conclusions Both vasopressin receptor 2 and 3 are expressed in ACTH-secreting tumors. Vasopressin receptor 2 rather than vasopressin receptor 3 is the primary receptor that seems to mediate the ACTH response in corticotrophin tumors. A vasopressin receptor 2 antagonist can inhibit ACTH secretion induced by desmopressin in AtT-20 cells.

Key words

pituitary - Cushing's disease - ectopic ACTH syndrome - vasopressin receptor 2 antagonist

• References

• 1 Maybauer MO, Maybauer DM, Enkhbaatar P. et al. Physiology of the vasopressin receptors. Best Pract Res Clin Anaesthesiol 2008; 22: 253-263
• 2 Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11: 406-410
• 3 Kojima Y, Suzuki S, Yamamura K. et al. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay. Endocr J 2002; 49: 285-292
• 4 Fiore C, Bailey D, Conlon N. et al. Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. J Clin Pathol 2012; 65: 496-502
• 5 Oldfield EH, Doppman JL, Nieman LK. et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential-diagnosis of cushings-syndrome. N Engl J Med 1991; 325: 897-905
• 6 Newell-Price J, Trainer P, Besser M. et al. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998; 19: 647-672
• 7 Kaltsas GA, Giannulis MG, Newell-Price JDC. et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84: 487-492
• 8 Dahia PLM, AhmedShuaib A, Jacobs RA. et al. Vasopressin receptor expression and mutation analysis in corticotrophin-secreting tumors. J Clin Endocrinol Metab 1996; 81: 1768-1771
• 9 de Keyzer Y, Lenne F, Auzan C. et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996; 97: 1311-1318
• 10 de Keyzer Y, Rene P, Beldjord C. et al. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol 1998; 49: 475-482
• 11 Machado MC, de Sa SV, Correa-Giannella ML. et al. Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients. Eur J Endocrinol 2008; 158: 605-613
• 12 Luque RM, Ibáñez-Costa A, López-Sánchez LM. et al. A cellular and molecular basis for the selective desmopressin-induced ACTH release in cushing disease patients: Key role of AVPR1b receptor and potential therapeutic implications. J Clin Endocrinol Metab 2013; 98: 4160-4169
• 13 Tsagarakis S, Tsigos C, Vasiliou V. et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: Constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87: 1646-1653
• 14 Arlt W, Dahia PLM, Callies F. et al. Ectopic ACTH production by a bronchial carcinoid tumour responsive to desmopressin in vivo and in vitro. Clin Endocrinol 1997; 47: 623-627
• 15 Chabot V, de Keyzer Y, Gebhard S. et al. Ectopic ACTH Cushing's syndrome: V3 vasopressin receptor but not CRH receptor gene expression in a pulmonary carcinoid tumor. Horm Res 1998; 50: 226-231
• 16 Richardson DW, Robinson AG. Drugs 5 Years Later-Desmopressin. Ann Intern Med 1985; 103: 228-239
• 17 Saito M, Tahara A, Sugimoto T. 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol 1997; 53: 1711-1717
• 18 Vassiliadi DA, Tsagarakis S. The role of the desmopressin test in the diagnosis and follow-up of Cushing’s syndrome. Eur J Endocrinol 2018; 178: 201-214
• 19 Tirabassi G, Faloia E, Papa R. et al. Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J Clin Endocrinol Metab 2010; 95: 1115-1122
• 20 Sakai Y, Horiba N, Tozawa F. et al. Desmopressin stimulation test for diagnosis of ACTH-Dependent Cushing’s syndrome. Endocr J 1997; 44: 687-695
• 21 Wang FF, Tang KT, Yen YS. et al. Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours. Clin Endocrinol 2012; 76: 253-263
• 22 Lutzbucher B, Jeandel L, Heisler S. et al. Evidence that AVP receptors in AtT-20 corticotrophs are not coupled to secretion of POMC-derived peptides. Mol Cell Endocrinol 1987; 53: 161-167
• 23 Ventura MA, Rene P, de Keyzer Y. et al. Gene and cDNA cloning and characterization of the mouse V3/V1b pituitary vasopressin receptor. J Mol Endocrinol 1999; 22: 251-260
• 24 Costello-Boerrigter LC, Boerrigter G, Burnett JC. Pharmacology of vasopressin antagonists. Heart Failure Rev 2010; 14: 75-82
• 25 Plosker GL. Tolvaptan. Drugs 2010; 40: 443-454
• 26 Schrier RW, Gross P, Gheorghiade M. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112
• 27 Gheorghiade M, Konstam MA, Burnett JC. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343
• 28 Pecori Giraldi F, Marini E, Torchiana E. et al. Corticotrophin-releasing activity of desmopressin in Cushing's disease: lack of correlation between in vivo and in vitro responsiveness. J Endocrinol 2003; 177: 373-379